Overview
ATHE market data
Price History
ATHE price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ATHE. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Alterity Therapeutics Receives Official Meeting Minutes From Fda End-of Phase-2 Meeting For ATH434 In Multiple System Atrophy; Pivotal Phase 3 Trial Activities On Track To Initiate By End Of 2026Benzinga · Jul 7, 2026, 11:20 AM
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16Benzinga · Jun 30, 2026, 1:25 PM
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular DisorderBenzinga · Jun 9, 2026, 3:45 PM
Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary EndpointBenzinga · Jun 9, 2026, 11:15 AM
Alterity Therapeutics Presents On Multiple System Atrophy Program Including Its Novel Imaging And Biomarker Approach, Phase 2 Data, And Current Plans To Advance ATH434 Into Phase 3 Clinical Development.Benzinga · May 19, 2026, 11:35 AM
Alterity Therapeutics Announces Publication Of Peer-Reviewed Study In NeuroImage Showing QSM MRI Can Detect Disease-Specific Iron Accumulation In Brains Of Patients With MSABenzinga · May 11, 2026, 11:28 AM